Dublin, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/zv...it_tablets ) has announced the addition of the "SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 " report to their offering.
Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitize the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms. In the United States, the only licensed route of administration is subcutaneous injection (SCIT). An alternative to SCIT is sublingual immunotherapy (SLIT). The medication is kept beneath the tongue where it is absorbed into the mucosa.
Though complex and not fully characterized mechanisms, administration of allergens through the oral, gingival, or sublingual mucosa can decrease the allergic response thus desensitizing the patient by modifying disease at least temporarily if not permanently (i.e. inducing tolerance). The incidence of severe or serious AE associated with SLIT is significantly lower than with SCIT such that SLIT which may be self-administered at home, while safe use of SCIT requires administration in a clinic that is capable of responding to systemic allergic reactions.
What You Will Learn
- What approved allergy immunotherapeutics (AIT) are currently marketed, how are they administered, what are the device specifics, and who markets them?
- Who are the important AIT suppliers, their manufacturing infrastructure and locations, their capabilities?
- What are the major factors driving demand for self-administered AIT products including SLIT tablets?
- How important are manufacturer relationships and what are the key alliances in the industry?
- What are the essential factors, issues, technologies and market development issues for self-administered AIT products?
- What are the significant economic, technology, and regulatory factors affecting AIT products?
Key Topics Covered:
1. Executive Summary
2. Allergy Immunotherapy Market Dynamics
- Competitive Landscape
- The Market for Allergy Immunotherapy
- Allergen Market Segments
- Pollen-based Allergies
- Possible Effects of Air Pollution in Allergic Diseases
- Dust Mites
- Pet Allergies
- Food Allergies
3. Therapeutic Market Segments
- Named Patient Products
- Prescription Products
- Emerging Therapeutic Segments
- Synthetic Peptide Epitopes
- Intralymphatic (ILIT) Administration
- Epicutaneous Administration
- Next Generation AIT
- Recombinant Allergens
4. Allergy Therapeutics Technology Platforms
- Contiguous Overlapping Peptides (Anergis)
- Sublingual Tablet Immunotherapy
- SLIT Tablet Formulations
- The Potential Role of Adjuvants
5. Approved SLIT Tablet Products
- U.S.
- Europe
6. Development-stage Sublingual Allergen Tablets
- Birch
- Dust Mite
- Grass
- Ragweed
7. Market Data and Forecasts
8. Market Factors
- Regulatory Factors and Issues
- United States
- Europe
- Japan
- The Shift from Named Patient to Prescription-based Marketing
- The Market Impact on OTC Rhinitis Treatment Products
- Clinical Trials and Product Development
- Managed Care & Healthcare Economics
9. Company Profiles
For more information visit http://www.researchandmarkets.com/research/zv...it_tablets
CONTACT: CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals
